Despite years of steady growth, investors have abandoned the stock featured this month because they believe the business is fading – it is being viewed almost like an Old Economy company, even though it is actually a technological pioneer. This company is poised to flip the narrative, sending the stock higher as investors realize it is an AI winner.
We recommend investors sell their position in the Saba Capital Income & Opportunities Fund (NYSE: BRW), to realize a gain of 29% since we first reported on it in 2023.
Last year, Ported unveiled an approach to investing where you don’t have to trade in and out of positions, where you don’t have to follow the news, and where you don’t even have to worry about the future. Now, he just made it even better.
In this week’s issue of The Big Secret On Wall Street, we perform a brief market analysis following the Fed’s rate cuts and a comprehensive portfolio review on four of our holdings as well as offering actions to take.
Our top Best Buys this month tried direct-to-consumer and sales slumped severely. Today, though, the company is helmed by a new and sensible CEO whose top priority has been getting its product off the internet and back into major retailers, with encouraging results that are reflected in recent earnings.
Some rare companies are so dominant in the marketplace that their brands actually become the business. The company featured this month is so dominant in its field that it should have been included in the “Legal Monopolies” portfolio category, but that legality is being called into question by the U.S. federal government.
The potential for a new biotech bull market means there has never been a better time to become a Biotech Frontiers subscriber. But that’s not the only reason to consider joining Erez Kalir’s service today… Read on to learn more!
In this week’s issue of The Big Secret On Wall Street, we perform a brief market analysis and a comprehensive portfolio review on six of our holdings as well as offering actions to take.
We have added two new companies to our Best Buys list of stocks that we feel are at a price that investors should seize on now – a pharma company and a tech firm join the cutting-edge tobacco company.
